Medical Utilization Associated with Palivizumab Compliance in a Commercial and Managed Medicaid Health Plan

BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections and hospitalization in infants. Palivizumab is currently the only available agent for prevention of RSV infection in highrisk infants. This high-cost injectable requires monthly dosing during the...

Descripción completa

Detalles Bibliográficos
Autores principales: Diehl, Jocelyn L., Daw, Jessica R., Coley, Kim C., Rayburg, Renee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437717/
https://www.ncbi.nlm.nih.gov/pubmed/20044844
http://dx.doi.org/10.18553/jmcp.2010.16.1.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437717/
https://www.ncbi.nlm.nih.gov/pubmed/20044844
http://dx.doi.org/10.18553/jmcp.2010.16.1.23

Ejemplares similares